Endoscopic and Symptomatic Outcomes of Vonoprazan for Erosive Esophagitis Following Laparoscopic Sleeve Gastrectomy: An Exploratory Prospective Study
Abstract
Background Gastroesophageal reflux disease (GERD) commonly occurs or worsens after laparoscopic sleeve gastrectomy (LSG); however, evidence regarding optimal medical management remains limited. This prospective study evaluated the endoscopic and symptomatic outcomes of Vonoprazan (VPZ), a potassium-competitive acid blocker, in erosive esophagitis (EE) following LSG.Methods Among 54 consecutive patients who underwent LSG, 19 who developed GERD symptoms within one year were included in the analysis. At symptom onset, esophagogastroduodenoscopy (EGD) was promptly performed to assess EE according to the Los Angeles (LA) classification, and the Frequency Scale for the Symptoms of GERD (FSSG) questionnaire was administered. All symptomatic patients were treated with VPZ (20 mg once daily for 4 weeks), after which EGD and FSSG assessments were repeated to evaluate therapeutic efficacy.Results Of the 19 patients, 16 (84.2%) had EE (LA grades A/B/C: 4/7/5), and 3 had non-erosive reflux disease (NERD). Among the patients with EE, 11 had de novo cases, and no grade C esophagitis was present preoperatively. The median interval to symptom onset was 40 days (range, 2-196 days). After 4 weeks of VPZ, complete mucosal healing was confirmed in all patients with EE (100% healing rate). The median FSSG scores in the EE group significantly improved from 28 (14-45) to 7 (1-31) (p<0.001).Conclusion Short-term improvements in the endoscopic findings and symptoms were observed after 4 weeks of VPZ treatment in patients with EE, which represented the majority of postoperative GERD cases in this cohort. Larger controlled studies are required to confirm these findings.
Related
- Baseline adipokine profiles have limited predictive value for weight-loss outcomes after laparoscopic sleeve gastrectomy: a prospective longitudinal cohort study
- Dynamic Changes in Serum Neutrophil Gelatinase-Associated Lipocalin for Discrimination of Creatinine-Defined Acute Kidney Injury After Laparoscopic Sleeve Gastrectomy: A Prospective Observational Cohort Study
- Laparoscopic Sleeve Gastrectomy With 75-mm Stapler Reloads: A Pilot Survey of Surgeon-Reported Workflow and Perceived Safety
- Association between anesthetic fresh gas flow and postoperative inflammatory response in laparoscopic sleeve gastrectomy : A retrospective cohort study
- Effects of Laparoscopic Sleeve Gastrectomy on Vascular and Myocardial Recovery: Type 2 Diabetes and Echocardiographic Indices of Diastolic Function
BibTeX
@article{okanobu2026endoscopic,
title = {{Endoscopic and Symptomatic Outcomes of Vonoprazan for Erosive Esophagitis Following Laparoscopic Sleeve Gastrectomy: An Exploratory Prospective Study}},
author = {Hideharu Okanobu and Kazuki Boda and Akihiro Sakai and Toshitsune Ikeda and Ryo Yuge and Nami Mori and Makoto Kobayakawa and Takenori Okada and Nozomu Kamei and Kenkichi Hashimoto},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.8093-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8093-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Endoscopic and Symptomatic Outcomes of Vonoprazan for Erosive Esophagitis Following Laparoscopic Sleeve Gastrectomy: An Exploratory Prospective Study
AU - Hideharu Okanobu
AU - Kazuki Boda
AU - Akihiro Sakai
AU - Toshitsune Ikeda
AU - Ryo Yuge
AU - Nami Mori
AU - Makoto Kobayakawa
AU - Takenori Okada
AU - Nozomu Kamei
AU - Kenkichi Hashimoto
PY - 2026
DA - 2026/09/29
JO - Internal Medicine
DO - 10.2169/internalmedicine.8093-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8093-26/_article
AB - Background Gastroesophageal reflux disease (GERD) commonly occurs or worsens after laparoscopic sleeve gastrectomy (LSG); however, evidence regarding optimal medical management remains limited. This prospective study evaluated the endoscopic and symptomatic outcomes of Vonoprazan (VPZ), a potassium-competitive acid blocker, in erosive esophagitis (EE) following LSG.Methods Among 54 consecutive patients who underwent LSG, 19 who developed GERD symptoms within one year were included in the analysis. At symptom onset, esophagogastroduodenoscopy (EGD) was promptly performed to assess EE according to the Los Angeles (LA) classification, and the Frequency Scale for the Symptoms of GERD (FSSG) questionnaire was administered. All symptomatic patients were treated with VPZ (20 mg once daily for 4 weeks), after which EGD and FSSG assessments were repeated to evaluate therapeutic efficacy.Results Of the 19 patients, 16 (84.2%) had EE (LA grades A/B/C: 4/7/5), and 3 had non-erosive reflux disease (NERD). Among the patients with EE, 11 had de novo cases, and no grade C esophagitis was present preoperatively. The median interval to symptom onset was 40 days (range, 2-196 days). After 4 weeks of VPZ, complete mucosal healing was confirmed in all patients with EE (100% healing rate). The median FSSG scores in the EE group significantly improved from 28 (14-45) to 7 (1-31) (p<0.001).Conclusion Short-term improvements in the endoscopic findings and symptoms were observed after 4 weeks of VPZ treatment in patients with EE, which represented the majority of postoperative GERD cases in this cohort. Larger controlled studies are required to confirm these findings.
SN - 1349-7235
SN - 0918-2918
ER -